ResMed (WBO:RMD) Gross-Profit-to-Asset % : 40.46% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is ResMed Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. ResMed's annualized Gross Profit for the quarter that ended in Mar. 2024 was €2,549 Mil. ResMed's average Total Assets over the quarter that ended in Mar. 2024 was €6,301 Mil. Therefore, ResMed's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 40.46%.

ResMed Gross-Profit-to-Asset % Historical Data

The historical data trend for ResMed's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ResMed Gross-Profit-to-Asset % Chart

ResMed Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

42.26

39.57

38.17

43.80

39.34

ResMed Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															36.71	36.46	35.85	37.52	40.46

Competitive Comparison of ResMed's Gross-Profit-to-Asset %

For the Medical Instruments & Supplies subindustry, ResMed's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ResMed's Gross-Profit-to-Asset % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where ResMed's Gross-Profit-to-Asset % falls into.

ResMed Gross-Profit-to-Asset % Calculation

ResMed's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2023 )	/	( (Total Assets (A: Jun. 2022 )	+	Total Assets (A: Jun. 2023 ))	/ count )
	=	2174.276	/	( (4820.677	+	6231.826)	/ 2 )
	=	2174.276	/	5526.2515
	=	39.34 %

ResMed's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	2549.436	/	( (6331.966	+	6269.397)	/ 2 )
	=	2549.436	/	6300.6815
	=	40.46 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

ResMed Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of ResMed's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

ResMed (WBO:RMD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (WBO:RMD) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

RSMDF:USA RMD:USA RMEA:Germany R1MD34:Brazil RMD:Australia

Address

9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123

Website

https://www.resmed.com

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.